Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Packaging: airtight package for oversea shipment
Transportation: Ocean,Land,Air,Express
Supply Ability: 5000KGS MONTHLY
Port: BEIJING,SHANGHAI,QINGDAO
Payment Type: L/C,T/T
Incoterm: FOB,CFR,CIF,EXW
GW786034 is a new oral angiogenesis inhibitor developed by GlaxoSmithKline that can interfere with the formation of new blood vessels required for the survival and growth of intractable tumors. It targets the vascular endothelial growth factor receptor (VEGFR). It works by inhibiting the formation of new blood vessels supplying the tumor. It is suitable for the treatment of advanced renal cell carcinoma (a type of kidney cancer in which cancer cells are found in the renal tubules), soft tissue sarcoma (STS), epithelial ovarian cancer and non-small cell lung cancer (NSCLC).
PRODUCT GW786034
CAS 444731-52-6
MF C21H23N7O2S
MW 437.52
Product Categories : API Intermediates > Pazopanib HCL Intermediate
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.